Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

William Casey Wilson, PhD, John Richards, PhD, Robyn J Puro, PhD, Gabriela Andrejeva, PhD, Ben J Capoccia, PhD, Mike J Donio, Ronald R Hiebsch, BS, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139655

Published: 2020

Journal Articles

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

John Richards, PhD, Myriam N Bouchlaka, BS,PhD, Robyn J Puro, PhD, Ben J Capoccia, PhD, Ronald R Hiebsch, BS, Michael J Donio, BS, W. Casey Wilson, PhD, Prabir Chakraborty, PhD, Victoria Sung, PhD, Daniel S Pereira, PhD

Blood (2019) 134 (Supplement_1): 1844.

https://doi.org/10.1182/blood-2019-126298

Published: 2019

Journal Articles

Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria

Fraser Macrae, BSc, PhD, Polly Bowman, Emma Linton, Barnaby Peacock-Young, Deborah Clarke, MSc, Darren J Newton, PhD, Claire E McKinley, BSc, Kathryn Riley, Nicola Copeland, Louise Arnold, Morag Griffin, Talha Munir, Peter Hillmen, MBChB, PhD, Stephen John Richards, PhD FRCPath, Robert Ariens, BSc, PhD, Anita Hill, MBChB (Hons), PhD

Blood (2017) 130 (Supplement 1): 462.

https://doi.org/10.1182/blood.V130.Suppl_1.462.462

Published: 2017

Journal Articles

Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria

Morag Griffin, Talha Munir, Peter Hillmen, MBChB, PhD, Louise Arnold, Nicola Copeland, Kathryn Riley, Stephen John Richards, PhD FRCPath, Anita Hill, MBChB (Hons), PhD

Blood (2017) 130 (Supplement 1): 1175.

https://doi.org/10.1182/blood.V130.Suppl_1.1175.1175

Published: 2017

Journal Articles

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Claire E McKinley, BSc, Stephen John Richards, PhD FRCPath, Talha Munir, Morag Griffin, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Louise Arnold, Kathryn Riley, Nicola Copeland, Darren J Newton, PhD, Anita Hill, MBChB (Hons), PhD, Peter Hillmen, MBChB, PhD

Blood (2017) 130 (Supplement 1): 3471.

https://doi.org/10.1182/blood.V130.Suppl_1.3471.3471

Published: 2017

Journal Articles

Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab: A UK Experience

Morag Griffin, Austin Kulasekararaj, MD, Shreyans Gandhi, MD DNB, MRCP, FRCPath, Peter Hillmen, Talha Munir, Stephen John Richards, PhD, Louise Arnold, BSc, MA, Kathryn Riley, Katherine Pelton, Nana Benson-Quarm, B.Sc, Dip (Nursing), Isabel Duggins, Judith C. W. Marsh, MD FRCP, FRCPath, Anita Hill

Blood (2016) 128 (22): 2683.

https://doi.org/10.1182/blood.V128.22.2683.2683

Published: 2016

Journal Articles

Clinical and Immunological Characterisation of Coversin, a Novel Small Protein Inhibitor of Complement C5 with Potential As a Therapeutic Agent in PNH and Other Complement Mediated Disorders

Wynne H Weston-Davies, MB FRCS, Miles A Nunn, DPhil, Fernando O Pinto, MDFRCPath, Ian J Mackie, PhDFRCPath, Stephen John Richards, PhD FRCPath, Samuel J Machin, MDFRCPath, Raymond Prudo, MB FRCP(C) MRCPsych, Peter Hillmen, MBChB, PhD

Blood (2014) 124 (21): 4280.

https://doi.org/10.1182/blood.V124.21.4280.4280

Published: 2014

Journal Articles

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Praveen Kaudlay, MBBS, MRCP, Haiying Hua, MD, Guansheng He, MD, Darren J Newton, PhD, Abraham M Varghese, MB ChB, Talha Munir, MBBS, MRCP, FRCPath, Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Stephen John Richards, PhD, Peter Hillmen, MB ChB, PhD

Blood (2013) 122 (21): 2466.

https://doi.org/10.1182/blood.V122.21.2466.2466

Published: 2013

Journal Articles

Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course

Stephen John Richards, PhD, Richard Kelly, MD, Anita Hill, MBChB, PhD, Anita Dickinson, MSc, Fiona Cullen, MSc, Jane Shingles, PhD, Matthew Cullen, MSc, Peter Hillmen, MB ChB, PhD

Blood (2013) 122 (21): 3718.

https://doi.org/10.1182/blood.V122.21.3718.3718

Published: 2013

Journal Articles

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

Anita Hill, MBChB, PhD, Richard J Kelly, MBChB, Austin G Kulasekararaj, MBBS, MD, Shreyans A Gandhi, MBBS, MD, Lindsay D Mitchell, MBChB, Modupe Elebute, MBChB, MD, Stephen John Richards, PhD, Matthew Cullen, MSc, Louise M Arnold, RN, BSc, Joanna Large, RN, BSc, Alexandra Wood, RN, BSc, Gemma L Brooksbank, RN, BSc, Tracy Downing, Claire McKinley, BSc, Dena Cohen, BSc, MSc, Walter M Gregory, PhD, Judith C. W. Marsh, MD, PhD, Ghulam J. Mufti, MD, Peter Hillmen, MBChB, PhD

Blood (2012) 120 (21): 3472.

https://doi.org/10.1182/blood.V120.21.3472.3472

Published: 2012

Journal Articles

An In Vitro model of the Bone Marrow in Paroxysmal Nocturnal Hemoglobinuria Showing a Direct Effect of T-Cells within the Bone Marrow Allowing Clonal Expansion

Richard J Kelly, MBChB, FRCPath, Stephen John Richards, PhD, FRCPath, Matthew Cullen, MSc, Louise M Arnold, RN, BSc, hons, Gemma L Brooksbank, RN, BSc, hons, Anita Hill, MBChB, PhD, Reuben Tooze, PhD, Gina M Doody, PhD, Peter Hillmen, MBChB, PhD

Blood (2011) 118 (21): 731.

https://doi.org/10.1182/blood.V118.21.731.731

Published: 2011

Journal Articles

Continued Benefit From Prolonged Treatment with Eculizumab in 130 Patients with PNH in the UK: Home Delivery of Eculizumab Is Safe, Convenient and Associated with Very High Levels of Patient Satisfaction

Louise M Arnold, RN, BSc, hons, Gemma L Brooksbank, RN, BSc, hons, Richard J Kelly, MBChB, FRCPath, Anita Hill, MBChB, PhD, Stephen John Richards, PhD, FRCPath, Rachel Senior, MPharm, Tracy Downing, Claire McKinley, BSc, James Brown, BMus, Ibrahim Momoh, RN, Modupe Elebute, MBBS, MD, Peter Hillmen, MBChB, PhD

Blood (2011) 118 (21): 4368.

https://doi.org/10.1182/blood.V118.21.4368.4368

Published: 2011

Journal Articles

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

Richard J Kelly, MBChB, MRCP(UK), FRCPath, Anita Hill, MBChB, MRCP(UK), FRCPath, PhD, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Stephen John Richards, PhD, FRCPath, Louise M Arnold, RN, BSc, hons, Gemma L Valters, RN, BSc, hons, Matthew Cullen, MSc, Dena R Cohen, MSc, Walter M Gregory, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 639.

https://doi.org/10.1182/blood.V116.21.639.639

Published: 2010

Journal Articles

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

Eugene A. Zhukovsky, PhD, Holly Horton, Ph.D, Matthias Peipp, PhD, Erik Pong, BS, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Seung Chu, PhD, Roland Repp, MD, John Desjarlais, PhD

Blood (2008) 112 (11): 881.

https://doi.org/10.1182/blood.V112.11.881.881

Published: 2008

Journal Articles

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Eugene Zhukovsky, PhD, Seung Chu, PhD, Matthew Bernett, PhD, Sher Karki, PhD, John Richards, PhD, Erik Pong, BS, Matthias Peipp, PhD, Roland Repp, MD, John Desjarlais, PhD

Blood (2007) 110 (11): 2335.

https://doi.org/10.1182/blood.V110.11.2335.2335

Published: 2007

NARROW

AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics

Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination

Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria

Thrombosis in Non-Hemolytic Paroxysmal Nocturnal Haemogloinuria

Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome

Concurrent Treatment of Aplastic Anaemia (AA) with Immunosuppressive Therapy and Paroxysmal Nocturnal Hemoglobinuria (PNH) with Eculizumab: A UK Experience

Clinical and Immunological Characterisation of Coversin, a Novel Small Protein Inhibitor of Complement C5 with Potential As a Therapeutic Agent in PNH and Other Complement Mediated Disorders

“Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Hemolysis and Provides a Rationale For C3 Inhibition.”

Insights Into The Natural History Of Paroxysmal Nocturnal Hemoglobinuria (PNH): Analysis Of The Presenting Clinical, Haematological and Flow Cytometric Features Of 705 Patients Leads To Improved Classification and Prediction Of Clinical Course

Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Report of All 153 Patients Treated in the UK

An In Vitro model of the Bone Marrow in Paroxysmal Nocturnal Hemoglobinuria Showing a Direct Effect of T-Cells within the Bone Marrow Allowing Clonal Expansion

Continued Benefit From Prolonged Treatment with Eculizumab in 130 Patients with PNH in the UK: Home Delivery of Eculizumab Is Safe, Convenient and Associated with Very High Levels of Patient Satisfaction

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

An Fc-Engineered Humanized Anti-CD40 Monoclonal Antibody, XmAb5485, Exhibits Potent Activity in Vitro and in Vivo against Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma

XmAb™ Fc Engineered Anti-CD19 Monoclonal Antibody with Enhanced In Vitro Efficacy Against Lymphoma and Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only